



PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Applicant Number	10/817,626	
			Filing Date	4/2/04	
			First Named Inventor	Scott et al.	
			Group Art Unit	1616	
			Examiner Name	Unknown	
Sheet	1	of	2	Attorney Docket Number	626-08-PA

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
AM		Blaser <i>Helicobacter pylori</i> and gastric diseases. BMJ 1998; 316: 1507-1510.	<input type="checkbox"/>
		Blaser Epidemiology and pathophysiology of <i>Camphyobacter pylori</i> infections. Rev Infec Dis 1990; 12(suppl 1): S99-S106.	<input type="checkbox"/>
		RUPNOW et al. A dynamic transmission model for predicting trends in <i>Helicobacter pylori</i> and associated diseases in the United States. Emerg Infect Dis 2000; 6: 228-237.	<input type="checkbox"/>
		UEMURA et al. <i>Helicobacter pylori</i> infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789	<input type="checkbox"/>
		Effect of <i>Helicobacter pylori</i> eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 639-642.	<input type="checkbox"/>
		AKRE et al. Risk for gastric cancer after antibiotic prophylaxis in patients undergoing hip replacement. Cancer Res. 2002; 60: 6376-6380.	<input type="checkbox"/>
		PENSTON et al. Eradication of <i>Helicobacter pylori</i> : an objective assessment of current therapies. Br J Clin Pharmacol 1997; 43: 223-243.	<input type="checkbox"/>
		Graham Antibiotic resistance in <i>Helicobacter Pylori</i> : implications for therapy. Gastroenterology, 1998; 115: 1272-1277.	<input type="checkbox"/>
		Megraud Resistance of <i>Helicobacter pylori</i> to antibiotics. Aliment Pharmacol Ther 1997; 11(Suppl. 1): 43-53.	<input type="checkbox"/>
		MEYER et al. Risk factors for <i>Helicobacter pylori</i> resistance in the United States: the Surveillance of H. pylori Anti;	<input type="checkbox"/>

Examiner Signature		Date Considered	8/4/05
-----------------------	--	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231



PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Applicant Number	10/817,626
Filing Date	4/2/04
First Named Inventor	Scott et al.
Group Art Unit	1616
Examiner Name	Unknown
Attorney Docket Number	626-08-PA

Sheet 2 of 2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
Bef		DORÉ et al. Effects of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of <i>Helicobacter pylori</i> therapy: a meta-analytical approach. Dig Dis Sci 2000; 45: 68-86.	<input type="checkbox"/>
		PUSCAS et al. Anhydrase inhibitors in the treatment of gastric and duodenal ulcers. Arch Fr Mal App Dig 1976; 65: 577-83.	<input type="checkbox"/>
		VALEAN S, VLAICU R, Ionescu I. Treatment of gastric ulcer with carbonic anhydrase inhibitors. Ann N Y Acad Sci 1984; 429: 597-600.	<input type="checkbox"/>
		PUSCAS et al. Puscas I Treatment of gastroduodenal ulcers with carbonic acid inhibitors. Ann NY Acad Sci 1984; 429: 587-591.	<input type="checkbox"/>
		ERDEI et al. Successful treatment of intractable gastric ulcers with acetazolamide. Acta Med Hung 1990; 47: 171-178	<input type="checkbox"/>
		MOBLEY et al. Molecular biology of microbial ureases. Microbiol Rev 1995; 59: 451-480.	<input type="checkbox"/>
		SCOTT et al. Expression of the <i>Helicobacter pylori</i> ureI Gene is Required for Acidic pH Activation of Cytoplasmic Urease. Infect Immun 2000; 68(2): 470-477.	<input type="checkbox"/>
ADP		MOLLENHAUER-REKTORSCHKE et al. Res Microbiol 2002; 153: 659-666.	<input type="checkbox"/>
		WEN et al. Acid adaptive genes of <i>Helicobacter pylori</i> . Infect Immun 2003; 71(10): 5921-5939.	<input type="checkbox"/>
ADP			<input type="checkbox"/>

Examiner
Signature

Date


Considered

8/7/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231



ATTORNEY DOCKET NO. 626-08-PA

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of) Examiner: Unknown
Scott, et al.) Art Unit: 1616
Serial No.: 10/817,626)
Filed: April 2, 2004)
For: Carbonic Anhydrase Inhibitors as)
Drugs to Eradicate Helicobacter Pylori in)
the Mammalian, Including Human,)
Stomach)

INFORMATION DISCLOSURE
STATEMENT

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate of Mailing




I hereby certify that this correspondence is being deposited on March 24, 2005
with the United States Postal Service First Class Mail addressed to: Mail Stop
DD, Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.


Toni Whyte

March 24, 2005
Date

Dear Sir:

Pursuant to 37 CFR Sections 1.97 and 1.98, and in fulfillment of the duty of candor set forth in 37 CFR Section 1.56, Applicant cites the following documents listed on Form 1449, submitted herewith. Copies of the references are enclosed.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Blaser <i>Helicobacter pylori</i> and gastric diseases. BMJ 1998; 316: 1507-1510.	<input type="checkbox"/>
		Blaser Epidemiology and pathophysiology of <i>Camphyobacter pylori</i> infections. Rev Infec Dis 1990; 12(suppl 1): S99-S106.	<input type="checkbox"/>
		RUPNOW et al. A dynamic transmission model for predicting trends in <i>Helicobacter pylori</i> and associated diseases in the United States. Emerg Infect Dis 2000; 6: 228-237.	<input type="checkbox"/>



	UEMURA et al. <i>Helicobacter pylori</i> infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-789	<input type="checkbox"/>
	Effect of <i>Helicobacter pylori</i> eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 639-642.	<input type="checkbox"/>
	AKRE et al. Risk for gastric cancer after antibiotic prophylaxis in patients undergoing hip replacement. Cancer Res. 2002; 60: 6376-6380.	<input type="checkbox"/>
	PENSTON et al. Eradication of <i>Helicobacter pylori</i> : an objective assessment of current therapies. Br J Clin Pharmacol 1997; 43: 223-243.	<input type="checkbox"/>
	Graham Antibiotic resistance in <i>Helicobacter Pylori</i> : implications for therapy. Gastroenterology, 1998; 115: 1272-1277.	<input type="checkbox"/>
	Megraud Resistance of <i>Helicobacter pylori</i> to antibiotics. Aliment Pharmacol Ther 1997; 11(Suppl. 1): 43-53.	<input type="checkbox"/>
	MEYER et al. Risk factors for <i>Helicobacter pylori</i> resistance in the United States: the Surveillance of H. pylori Anti;	<input type="checkbox"/>
	DORE et al. Effects of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of <i>Helicobacter pylori</i> therapy: a meta-analytical approach. Dig Dis Sci 2000; 45: 68-86.	<input type="checkbox"/>
	PUSCAS et al. Anhydrase inhibitors in the treatment of gastric and duodenal ulcers. Arch Fr Mal App Dig 1976; 65: 577-83.	<input type="checkbox"/>
	VALEAN S, VLAICU R, Ionescu I. Treatment of gastric ulcer with carbonic anhydrase inhibitors. Ann N Y Acad Sci 1984; 429: 597-600.	<input type="checkbox"/>
	PUSCAS et al. Puscas I Treatment of gastroduodenal ulcers with carbonic acid inhibitors. Ann NY Acad Sci 1984; 429: 587-591.	<input type="checkbox"/>
	ERDEI et al. Successful treatment of intractable gastric ulcers with acetazolamide. Acta Med Hung 1990; 47: 171-178	<input type="checkbox"/>
	MOBLEY et al. Molecular biology of microbial ureases. Microbiol Rev 1995; 59: 451-480.	<input type="checkbox"/>
	SCOTT et al. Expression of the <i>Helicobacter pylori</i> ureI Gene is Required for Acidic pH Activation of Cytoplasmic Urease. Infect Immun 2000; 68(2): 470-477.	<input type="checkbox"/>
	MOLLENHAUER-REKTORSCHKE et al. Res Microbiol 2002; 153: 659-666.	<input type="checkbox"/>
	WEN et al. Acid adaptive genes of <i>Helicobacter pylori</i> . Infect Immun 2003; 71(10): 5921-5939.	<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>